Table 1. Human brain tissue of Alzheimer's disease (AD) and control (Con) cases used in this study.

Case	Age at death (years)	Gender	PMI (h)	Braak stagea	Tangle scoresb
AD1c	89	F	3.0	V	14.5
AD2c	80	F	2.25	VI	14.5
AD3c	85	F	1.66	V	12.0
AD4c	78	F	1.83	VI	15.0
AD5c	95	F	3.16	VI	10.0
AD6c	86	M	2.25	VI	13.5
AD7c	91	F	3.0	V	8.5
AD8d	83	F	3.0	VI	12.4
AD9d	74	M	2.75	VI	14.66
AD10d	79	F	1.5	VI	14.66
AD11d	73	F	2.0	V	15.00
AD12d	81	M	3.0	V	11.00
AD13d	76	M	2.33	VI	15.00
AD14d	72	M	2.5	VI	15.00
AD15d	74	F	2.83	VI	15.00
AD16d	76	M	4.0	V	15.00
AD17d	78	M	1.83	VI	15.00
Mean ± S.D.	80.59 ± 6.70		2.52 ± 0.65		13.57 ± 2.05
Con1d	85	F	2.75	II	5.0
Con2d	82	F	2.0	II	4.25
Con3d	70	F	2.0	I	0.00
Con4d	73	M	2.0	III	2.75
Con5d	78	M	1.66	I	0.00
Con6d	80	M	3.25	I	2.75
Con7d	80	M	2.16	II	1.00
Con8d	83	F	3.25	I	0.75
Con9d	82	F	2.25	II	3.50
Con10d	85	M	2.5	II	4.25
Con11c	85	M	2.5	II	4.25
Con12c	86	F	2.5	III	5.00
Con13c	81	M	2.75	III	6.41
Con14c	88	F	3.0	II	2.00
Con15c	90	F	3.0	III	4.50
Con16c	88	F	3.5	III	2.50
Con17c	88	F	3.0	IV	4.50
Mean ± S.D.	82.59 ± 5.50		2.59 ± 0.53		3.14 ± 1.89

Abbreviation: PMI, postmortem interval.

^aNeurofibrillary pathology was staged according to Braak and Braak (1995).

^bTangle score was a density estimate and was designated none, sparse, moderate, or frequent (0, 1, 2 or 3 for statistics), as defined according to CERADAD criteria. Five areas (frontal, temporal, parietal, hippocampal, and entorhinal) were examined, and the scores were added up for a maximum of 15.

^cCases were used for measurement of tau and TDP-43 in the frontal cortex and cerebellum.

^dCases were used for tau measurement by immune-dot-blots.